The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

While it’s largely preventable through vaccines such as Sanofi’s own MenQuadfi, infection of the most severe form, bacterial meningitis, can be fatal within just 24 hours and remains a ...

Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...